Highlights Adagene Inc.

Equities

ADAG

US0053291078

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-31 pm EDT			5-day change	1st Jan Change
2.8 ^USD	+7.90%		+8.53%	+44.97%

Mar. 29	Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 29	Adagene Inc. Announces Board Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Adagene Gets China Clearance to Assess Colorectal Cancer Treatment Combination	Feb. 09	MT
Adagene Inc. Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody	Feb. 09	CI
Adagene Inc. Announces Data from its Presentation at the American Society of Clinical Oncology 2024 Gastrointestinal (GI) Cancers Symposium	Jan. 16	CI
Adagene Inc. Presents Data Demonstrating the Best-In-Class Therapeutic Index for Masked Anti-CTLA-4 Safebody®? Adg126	Nov. 03	CI
Adagene Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Adagene Inc.'s Equity Buyback announced on June 29, 2022, has expired.	23-06-27	CI
Adagene Achieves $3 Million Milestone in Collaboration with Exelixis for Successful Nomination of Second Safebody® Novel Masked Antibody-Drug Conjugate	23-05-04	CI
Tranche Update on Adagene Inc.'s Equity Buyback Plan announced on June 29, 2022.	23-04-28	CI
Tranche Update on Adagene Inc.'s Equity Buyback Plan announced on June 29, 2022.	23-04-28	CI
Tranche Update on Adagene Inc.'s Equity Buyback Plan announced on June 29, 2022.	23-04-28	CI
Tranche Update on Adagene Inc.'s Equity Buyback Plan announced on July 7, 2021.	23-04-28	CI
Tranche Update on Adagene Inc.'s Equity Buyback Plan announced on July 7, 2021.	23-04-28	CI
Adagene Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28	CI
Adagene Announces Interim Data Demonstrating Safety and Confirmed Clinical Responses of Anti-Ctla-4 Safebody® Adg126 Up to 10 Mg/Kg with Repeat Cycles in Combination with Anti-Pd-1 Therapy from Dose Escalation Portion of Phase 1B/2 Trial	23-01-09	CI
Adagene, Roche Partner to Assess ADG126 Combined With Atezolizumab, Bevacizumab in Advanced Liver Cancer Trial	22-12-16	MT
Adagene Announces Clinical Trial Collaboration to Evaluate Anti-CTLA-4 SAFEbodyÂ® ADG126 in Combination with Rocheâ€™s Standard-of-Care for First-Line Advanced Liver Cancer	22-12-16	CI
Adagene Announces Clinical Data at SITC 2022 on Anti-CTLA-4 NEObody™, ADG116, Showing Differentiated Safety and Anti-tumor Activity in Heavily Pre-treated Patients with Difficult-to-Treat Tumors	22-11-10	CI
Adagene Inc. Presents Interim Monotherapy Data at ESMO 2022 Showing Compelling Safety, Anti-Tumor Activity and Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in Patients with Advanced Tumors	22-09-10	CI
Adagene Inc.'s Equity Buyback announced on July 7, 2021, has expired with 1,406,585 shares, representing 3.23% for $7.50 million.	22-07-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Adagene Inc.

Equities

ADAG

US0053291078

Highlights

Filters